Serial Number | 90545043 |
Word Mark | RENAGADE |
Filing Date | Wednesday, February 24, 2021 |
Status | 732 - THIRD EXTENSION - GRANTED |
Status Date | Friday, August 30, 2024 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
Published for Opposition Date | Tuesday, January 17, 2023 |
Goods and Services | Pharmaceutical preparations and substances, namely, RNA and DNA therapeutics for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention of osteoporosis; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of viral infections; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for treating diabetes; pharmaceutical preparations, namely, RNA and DNA therapeutics for use in chemotherapy; pharmaceutical preparations, namely, RNA and DNA therapeutics for cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, antivirals; therapeutic pharmaceuticals, namely, RNA and DNA therapeutics for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; vaccine preparations, namely, RNA and DNA vaccine preparations; vaccines, namely, RNA and DNA vaccines; anti-epileptic pharmaceutical preparations; Biometallic compounds being a component in pharmaceutical preparations for cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; human vaccine preparations, namely, RNA and DNA vaccine preparations; medical preparations for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; medicinal preparations for the treatment of infectious diseases and for use in oncology; mixed biological preparations, namely, RNA and DNA therapeutics for the prevention and treatment of infectious diseases; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; pharmaceutical preparations for the treatment of viral diseases; pharmaceutical products, namely, RNA and DNA therapeutics for the treatment of joint disease; pharmaceutical products, namely, RNA and DNA therapeutics for the treatment of viral and infectious diseases, for the treatment of cancer; therapeutic vaccines, namely, RNA and DNA therapeutics; all of the foregoing excluding medicinal dietary and nutritional supplements |
Pseudo Mark | RENEGADE |
International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
Class Status Code | 6 - Active |
Class Status Date | Wednesday, May 26, 2021 |
Primary Code | 005 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Party Name | Renagade Therapeutics LLC |
Party Type | 20 - Owner at Publication |
Legal Entity Type | 16 - Limited Liability Company |
Address | Cambridge, MA 02142 |
Party Name | Renagade Therapeutics LLC |
Party Type | 10 - Original Applicant |
Legal Entity Type | 16 - Limited Liability Company |
Address | Cambridge, MA 02142 |
Event Date | Event Description |
Saturday, February 27, 2021 | NEW APPLICATION ENTERED |
Wednesday, May 26, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Wednesday, September 15, 2021 | ASSIGNED TO EXAMINER |
Wednesday, September 15, 2021 | NON-FINAL ACTION WRITTEN |
Wednesday, September 15, 2021 | NON-FINAL ACTION E-MAILED |
Wednesday, September 15, 2021 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Tuesday, March 29, 2022 | TEAS PETITION TO REVIVE RECEIVED |
Tuesday, March 29, 2022 | PETITION TO REVIVE-GRANTED |
Tuesday, March 29, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Tuesday, March 29, 2022 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
Tuesday, March 29, 2022 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
Wednesday, March 30, 2022 | NOTICE OF REVIVAL - E-MAILED |
Thursday, March 31, 2022 | ASSIGNED TO LIE |
Thursday, March 31, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Thursday, March 31, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
Wednesday, May 4, 2022 | FINAL REFUSAL WRITTEN |
Wednesday, May 4, 2022 | FINAL REFUSAL E-MAILED |
Wednesday, May 4, 2022 | NOTIFICATION OF FINAL REFUSAL EMAILED |
Thursday, October 13, 2022 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
Thursday, October 13, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
Thursday, October 13, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
Thursday, October 13, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
Thursday, October 13, 2022 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
Friday, November 4, 2022 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
Friday, November 4, 2022 | EXPARTE APPEAL RECEIVED AT TTAB |
Friday, November 4, 2022 | JURISDICTION RESTORED TO EXAMINING ATTORNEY |
Friday, November 4, 2022 | EX PARTE APPEAL-INSTITUTED |
Monday, November 14, 2022 | ASSIGNED TO LIE |
Monday, November 14, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Monday, November 14, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
Wednesday, December 14, 2022 | APPROVED FOR PUB - PRINCIPAL REGISTER |
Wednesday, December 21, 2022 | EXPARTE APPEAL TERMINATED |
Wednesday, December 28, 2022 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Tuesday, January 17, 2023 | PUBLISHED FOR OPPOSITION |
Tuesday, January 17, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Tuesday, March 14, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
Wednesday, April 12, 2023 | SOU TEAS EXTENSION RECEIVED |
Wednesday, April 12, 2023 | SOU EXTENSION 1 FILED |
Wednesday, April 12, 2023 | SOU EXTENSION 1 GRANTED |
Friday, April 14, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Friday, January 26, 2024 | SOU TEAS EXTENSION RECEIVED |
Friday, January 26, 2024 | SOU EXTENSION 2 FILED |
Friday, January 26, 2024 | SOU EXTENSION 2 GRANTED |
Tuesday, January 30, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Friday, August 30, 2024 | SOU TEAS EXTENSION RECEIVED |
Friday, August 30, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Friday, August 30, 2024 | SOU EXTENSION 3 FILED |
Friday, August 30, 2024 | SOU EXTENSION 3 GRANTED |